早期SLE队列中ACR-1997、SLICC-2012与EULAR/ACR-2019分类标准划分非重叠患者群:联合使用三标准可优化临床研究入组
在病程中位48个月的早期SLE队列(SLE 690例,对照401例)中比较三种分类标准,发现SLICC-2012和EULAR/ACR-2019敏感性高于ACR-1997且能更早分类,但仅76.7%的SLE患者满足全部三标准,提示分类群体非重叠;修改算法可提高敏感性并可能利于早期治疗。
要点
- SLICC-2012和EULAR/ACR-2019敏感性高于ACR-1997,EULAR/ACR-2019特异性最高。
- 仅76.7%的SLE患者满足全部三种标准,分类群体非重叠。
- 修改EULAR/ACR和SLICC算法可提高敏感性,但特异性轻度下降。
核心结论
- SLICC-2012和EULAR/ACR-2019在早期SLE中比ACR-1997更敏感,EULAR/ACR-2019特异性更优,但仍有显著疾病患者被漏诊。
- 联合使用三种标准或修改算法可提高敏感性,可能促进早期分类和治疗。
研究设计与样本
- 研究纳入690例SLE患者和401例对照疾病患者,SLE队列中位病程48个月。
- 计算各标准的敏感性和特异性,并从随机80%数据集中推导修改分类算法,在剩余20%中验证。
主要发现
- 末次评估时,ACR-1997、SLICC-2012和EULAR/ACR-2019的敏感性分别为85.7%、91.3%和88.6%,特异性分别为93.0%、93.8%和97.3%。
- SLICC-2012和EULAR/ACR-2019均能更早分类;仅76.7%的SLE患者满足全部三种标准。
- 未分类患者中BILAG中/重度表现患病率为43.3%-60%,SLICC/ACR器官损伤为30%-50%。
- 诊断时,各标准漏诊25.6%-30.5%的患者。
- 修改EULAR/ACR和SLICC算法(纳入低补体血症和/或抗磷脂抗体阳性作为替代入门标准,和/或允许更少的多器官临床标准分类)后,诊断时敏感性中位数分别升至82.0%和86.2%,总体敏感性分别升至93.7%和97.1%,特异性轻度下降。
关键数值与推荐
- ACR-1997标准敏感性85.7%、特异性93.0%;SLICC-2012标准敏感性91.3%、特异性93.8%;EULAR/ACR-2019标准敏感性88.6%、特异性97.3%。
- 仅76.7%的SLE患者满足全部三种标准。
- 诊断时各标准漏诊25.6%-30.5%的患者。
- 修改后EULAR/ACR和SLICC算法诊断时敏感性中位数分别为82.0%和86.2%,总体敏感性分别为93.7%和97.1%。
临床怎么用
- 在早期SLE临床研究中,可考虑联合使用ACR-1997、SLICC-2012和EULAR/ACR-2019标准以优化患者捕获。
- 修改分类算法或可提高敏感性,但需权衡特异性轻度下降,并关注仍被漏诊的轻症患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Classification criteria are biased towards classifying long-standing disease. We compared the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)-2019, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and ACR-1997 criteria in an early (median 48 months) systemic lupus erythematosus (SLE) cohort. METHODS: Patients diagnosed with SLE (n=690) or control diseases (n=401). Sensitivity, specificity of the criteria and time-to-classification were calculated. Modified classification algorithms were derived from a random 80% and validated in the remaining 20% of the dataset running multiple iterations. RESULTS: At last assessment, sensitivities of ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria were 85.7%, 91.3% and 88.6%, with specificities 93.0%, 93.8% and 97.3%, respectively. Both SLICC and EULAR/ACR enabled earlier classification. Only 76.7% of patients with SLE met all three criteria suggesting non-overlapping groups. Notably, unclassified patients had high prevalence of British Isles Lupus Assessment Group moderate/severe manifestations (43.3%-60%) and SLICC/ACR organ damage (30%-50%). At diagnosis, criteria missed 25.6%-30.5% of patients. Modification of EULAR/ACR and SLICC algorithms to include hypocomplementaemia and/or positive anti-phospholipid antibodies as alternative entry criterion, and/or allow classification with fewer clinical criteria from multiple organs, increased their sensitivity at diagnosis (median 82.0% and 86.2%) and overall (93.7% and 97.1%) with modest decreases in specificity. Importantly, patients who were still missed by the modified criteria had lower incidence of major organ involvement, use of immunosuppressive/biological therapies and organ damage. CONCLUSIONS: The SLICC and EULAR/ACR are more sensitive than the ACR and the EULAR/ACR criteria have superior specificity in early SLE, although patients with significant disease can be missed. Combination and/or modification of the classification algorithms may enhance their sensitivity, allowing earlier classification and treatment of more patients with high disease burden.
引用
- Adamichou C, Nikolopoulos D, Genitsaridi I, et al. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis. 2019. PMID: 31704720. doi:10.1136/annrheumdis-2019-216155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。